Cu(ii)atsm    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis4
6Parkinson disease1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04313166
(ClinicalTrials.gov)
March 19, 202015/3/2020Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001Amyotrophic Lateral SclerosisDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLRecruiting18 Years75 YearsAll70Phase 2Australia
2NCT04082832
(ClinicalTrials.gov)
September 30, 20192/9/2019CuATSM Compared With Placebo for Treatment of ALS/MNDA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseAmyotrophic Lateral SclerosisDrug: Cu(II)ATSM;Drug: PlacebosCollaborative Medicinal Development Pty LimitedNULLRecruiting18 Years75 YearsAll80Phase 2;Phase 3Australia
3NCT03136809
(ClinicalTrials.gov)
January 18, 201828/4/2017ALS Treatment Extension StudyA Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001Amyotrophic Lateral SclerosisDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLActive, not recruiting18 Years75 YearsAll28Phase 1;Phase 2Australia
4NCT02870634
(ClinicalTrials.gov)
November 16, 201610/8/2016Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MNDA Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLCompleted18 Years75 YearsAll50Phase 1Australia

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03204929
(ClinicalTrials.gov)
August 14, 201728/6/2017Dose Escalation Study of Cu(II)ATSM in Parkinson's DiseaseA Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLCompleted30 YearsN/AAll31Phase 1Australia